Cargando…

S2.1 Enzyme replacement therapy (ERT) in Glycogen Storage Disease Type II: the first treatment developed

Detalles Bibliográficos
Autores principales:	Angelini, Corrado, Semplicini, Claudio, Fanin, Marina, Nascimbeni, Annachiara, Peterle, Enrico, Pegoraro, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pacini Editore SpA 2011
Materias:	Session 2. Management of Pompe Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298097/

Ejemplares similares

S2.2 Enzyme replacement therapy in the infantile-onset Pompe disease
por: Parenti, Giancarlo, et al.
Publicado: (2011)

S2.5 The nutritional approach to Pompe disease
por: Esposito, Katia, et al.
Publicado: (2011)

S2.4 The role of rehabilitation in the management of metabolic myopathies
por: Riccio, Ilaria, et al.
Publicado: (2011)

S2.3 Therapeutic approaches in the late onset form of GSD II
por: Musumeci, Olimpia, et al.
Publicado: (2011)

P-2 Two sisters with muscle lipid storage and carnitine deficiency in muscle and plasma
por: Angelini, C., et al.
Publicado: (2011)

Enzyme replacement therapy (ERT) in pompe disease
por: Fiumara, Agata
Publicado: (2014)

Transcriptional and Translational Effects of Intronic CAPN3 Gene Mutations
por: Nascimbeni, Anna Chiara, et al.
Publicado: (2010)

Muscle fatigue, nNOS and muscle fiber atrophy in limb girdle muscular dystrophy
por: ANGELINI, CORRADO, et al.
Publicado: (2014)

Autophagy dysregulation in Danon disease
por: Nascimbeni, Anna Chiara, et al.
Publicado: (2017)

S3.1 Are there ERT defined guidelines for Pompe disease?
por: Toscano, Antonio, et al.
Publicado: (2011)

Lipolysis and lipophagy in lipid storage myopathies
por: Angelini, Corrado, et al.
Publicado: (2016)

S1.6 Dry blood spot: a new method for early diagnosis
por: Donati, M.A.
Publicado: (2011)

S1.5 Role of the pulmonologist in the late-onset Pompe disease
por: Fiorentino, Giuseppe, et al.
Publicado: (2011)

S1.2 The pediatrician and the early onset Pompe disease
por: Fecarotta, Simona, et al.
Publicado: (2011)

S1.3 Adult-onset Pompe disease
por: Di Iorio, Giuseppe, et al.
Publicado: (2011)

S1.4 Cardiovascular involvement in Pompe disease
por: Limongelli, Giuseppe, et al.
Publicado: (2011)

S1.1 Introductory notes to Pompe disease and aims of the Meeting
por: Sampaolo, Simone, et al.
Publicado: (2011)

Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies
por: Bello, Luca, et al.
Publicado: (2016)

Evaluation of muscle biopsy in late-onset GSDII patients before and after enzyme replacement therapy (ERT)
por: Violano, R, et al.
Publicado: (2013)

Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
por: ANGELINI, CORRADO, et al.
Publicado: (2012)

Estrogen replacement therapy (ERT) in high-risk cancer patients.
por: Hutchinson-Williams, K. A., et al.
Publicado: (1991)

Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in Adult Pompe disease
por: Sayeed, Nadia, et al.
Publicado: (2015)

Proceedings of the XI Congress of the Italian Association of Myology Cagliari, May 2011: LGMD 1(F) - A pathogenetic hypothesis based on histopathology and ultrastructure
por: Cenacchi, G., et al.
Publicado: (2011)

Monday, May 12, 2008: Poster Session 2
Publicado: (2008)

Sunday, June 27, 2010: Poster Session 2
Publicado: (2010)

65: SEVERE MALARIA IN CANADA: 2018–2021 UPDATE FROM THE CANADIAN MALARIA NETWORK
por: Poenaru, S., et al.
Publicado: (2022)

54: THE IMPACT OF THE CORONAVIRUS DISEASE PANDEMIC ON RESPIRATORY-RELATED INFECTIONS IN JAPAN
por: Kitagawa, D., et al.
Publicado: (2022)

63: A MICROBIOLOGICAL RETROSPECTIVE REVIEW OF BLOOD STREAM INFECTIONS IN COVID-19 PATIENTS FROM A TERTIARY CARE CENTER IN LEBANON
por: Nahhal, S., et al.
Publicado: (2022)

69: COMPARING THE OUTCOMES OF GIVING TOCILIZUMAB THEN HEMOPERFUSION, HEMOPERFUSION THEN TOCILIZUMAB, AND NO INTERVENTION IN CRITICAL SARS-COV-2 PNEUMONIA PATIENTS IN MAKATI MEDICAL CENTER
por: Macatangay, M.V.R., et al.
Publicado: (2022)

64: BACTERIAL RESPIRATORY INFECTIONS IN PATIENTS WITH COVID-19: A RETROSPECTIVE STUDY FROM A TERTIARY CARE CENTER IN LEBANON
por: Shmoury, A., et al.
Publicado: (2022)

61: SECONDARY INFECTION DURING THE THIRDWAVE OF COVID-19 IN A HOSPITAL IN KATHMANDU
por: Baishnab, S.K. Mishra
Publicado: (2022)

58: SARS-COV-2 ANTIBODY CHARACTERISTICS OF SALIVA FROM VACCINATED INDIVIDUALS
por: Ota, K., et al.
Publicado: (2022)

Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy
por: Marzorati, Mauro, et al.
Publicado: (2012)

Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series
por: Lampe, Christina, et al.
Publicado: (2014)

Successful twin pregnancy in a 38-year-old woman with Pompe disease despite interruption of enzyme replacement therapy (ERT)
por: Tiling, N, et al.
Publicado: (2013)

Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis
por: Lee, Chung-Lin, et al.
Publicado: (2022)

Enzyme Replacement Therapy (ERT) on Heart Function Changes the Outcome in Patients with Infantile-Onset Pompe Disease: A Familial History
por: Lecis, Marco, et al.
Publicado: (2023)

MiRNAs as biomarkers of phenotype in neutral lipid storage disease with myopathy
por: Pegoraro, Valentina, et al.
Publicado: (2019)

A preliminary study of telemedicine for patients with hepatic glycogen storage disease and their healthcare providers: from bedside to home site monitoring
por: Hoogeveen, Irene J., et al.
Publicado: (2018)

Glycogen storage diseases: An update
por: Gümüş, Ersin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ltsi29gnsen87aht19lr77jv49